ABSTRACT
This chapter discusses access of a prescription drug that has gained market authorization from US Food and Drug Administration, European European Medicines Agency, etc. This access requires a concerted effort as many hurdles and endorsements that will impact actual prescribing and patient use. Differences between official list price and actual net price can be substantial, particularly in highly competitive therapy areas. US pharma companies spend well over $100 billion on rebates annually – more than twice all other selling, general and administrative expenses. Formulary adoption by public and private payers is obviously a critical step in reaching the patient. Provider organizations include a large range of integrated healthcare systems, specialty clinicals, hospitals and physician groups that put policies in place that influence treatment and prescribing behaviors of its associated physicians in varying degrees. The actual physician prescribing decision will continue to be central factor in the market adoption of any drug.
